Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice
Open Access
- 22 December 2018
- journal article
- research article
- Published by Springer Nature in BMC Veterinary Research
- Vol. 14 (1) , 1-11
Abstract
Vaccination is the principal strategy for prevention and control of diseases, and adjuvant use is an effective strategy to enhance vaccine efficacy. Traditional mineral oil-based adjuvants have been reported with post-immunization reactions. Developing new adjuvant formulations with improved potency and safety will be of great value. In the study reported herein, a novel oil-in-water (O/W) Emulsion Adjuvant containing Squalane (termed EAS) was developed, characterized and investigated for swine influenza virus immunization. The data show that EAS is a homogeneous nanoemulsion with small particle size (~ 105 nm), low viscosity (2.04 ± 0.24 cP at 20 °C), excellent stability (at least 24 months at 4 °C) and low toxicity. EAS-adjuvanted H3N2 swine influenza vaccine was administrated in mice subcutaneously to assess the adjuvant potency of EAS. The results demonstrated that in mice EAS-adjuvanted vaccine induced significantly higher titers of hemagglutination inhibition (HI) and IgG antibodies than water-in-oil (W/O) vaccines or antigen alone, respectively, at day 42 post vaccination (dpv) (P < 0.05). EAS-adjuvanted vaccine elicited significantly stronger IgG1 and IgG2a antibodies and higher concentrations of Th1 (IFN-γ and IL-2) cytokines compared to the W/O vaccine or antigen alone. Mice immunized with EAS-adjuvanted influenza vaccine conferred potent protection after homologous challenge. The O/W emulsion EAS developed in the present work induced potent humoral and cellular immune responses against inactivated swine influenza virus, conferred effective protection after homologous virus challenge and showed low toxicity in mice, indicating that EAS is as good as the commercial adjuvant MF59. The superiority of EAS to the conventional W/O formulation in adjuvant activity, safety and stability will make it a potential veterinary adjuvant.Keywords
Funding Information
- National Natural Science Foundation of China (31772701, 31672515, 31472164)
This publication has 41 references indexed in Scilit:
- Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferretsProceedings of the National Academy of Sciences, 2012
- Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsionsVaccine, 2011
- Taurine attenuates Streptococcus uberis-induced mastitis in rats by increasing T regulatory cellsAmino Acids, 2011
- Relationship between the size of nanoparticles and their adjuvant activity: Data from a study with an improved experimental designEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Interspecies and intraspecies transmission of triple reassortant H3N2 influenza A virusesVirology Journal, 2007
- Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanusVeterinary Immunology and Immunopathology, 2006
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- Vaccine adjuvants: Current state and future trendsImmunology & Cell Biology, 2004
- Th2 Responses to Inactivated Influenza Virus Can Be Converted to Th1 Responses and Facilitate Recovery from Heterosubtypic Virus InfectionThe Journal of Infectious Diseases, 1999